CD59 Human shRNA Plasmid Kit (Locus ID 966)

CAT#: TL316484

CD59 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector, 5µg of each construct provided



Need custom shRNA service?
Get a free quote

参与“shRNA产品第二件享半价”限时优惠活动

CNY 5,740.00


货期*
现货

规格
    • 1 kit

Product images

经常一起买 (4)
Lenti-vpak packaging kit - packaging plasmids and transfection reagent
    • 10 reactions

CNY 5,420.00


TurboFectin Transfection Reagent (1 mL in 1 vial)
    • 1 ml in 1 vial

CNY 4,090.00


CD59 mouse monoclonal antibody, clone OTI2E11 (formerly 2E11)
    • 100 ul

CNY 1,999.00
CNY 2,700.00


Lateral flow testing sticks used for the semi-quantitative detection of the lentiviral p24 protein, 20 tests
    • 20 Tests

CNY 4,070.00

Specifications

Product Data
Product Name CD59 Human shRNA Plasmid Kit (Locus ID 966)
Locus ID 966
UniProt ID P13987
Synonyms 1F5; 16.3A5; EJ16; EJ30; EL32; G344; HRF-20; HRF20; MAC-IP; MACIF; MEM43; MIC11; MIN1; MIN2; MIN3; MIRL; MSK21; p18-20
Vector pGFP-C-shLenti
Format Lentiviral plasmids
Kit Components CD59 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 966). 5µg purified plasmid DNA per construct
29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free.
RefSeq NM_000611, NM_001127223, NM_001127225, NM_001127226, NM_001127227, NM_203329, NM_203330, NM_203331, NM_203329.1, NM_203329.2, NM_203331.1, NM_203331.2, NM_000611.1, NM_000611.2, NM_000611.3, NM_000611.4, NM_000611.5, NM_203330.1, NM_203330.2, NM_001127223.1, NM_001127227.1, NM_001127225.1, NM_001127226.1, BC001506, BC001506.2, BC033226, BM457931, BM551313, BM680161, BM724931, BM829941, BM911556, NM_000611.6
Summary This gene encodes a cell surface glycoprotein that regulates complement-mediated cell lysis, and it is involved in lymphocyte signal transduction. This protein is a potent inhibitor of the complement membrane attack complex, whereby it binds complement C8 and/or C9 during the assembly of this complex, thereby inhibiting the incorporation of multiple copies of C9 into the complex, which is necessary for osmolytic pore formation. This protein also plays a role in signal transduction pathways in the activation of T cells. Mutations in this gene cause CD59 deficiency, a disease resulting in hemolytic anemia and thrombosis, and which causes cerebral infarction. Multiple alternatively spliced transcript variants, which encode the same protein, have been identified for this gene. [provided by RefSeq, Jul 2008]
shRNA Design These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service.
Performance Guaranteed OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.
Customer Reviews 
Loading...